Fluorescence Resonance Energy Transfer–Based Sensor Camui Provides New Insight Into Mechanisms of Calcium/Calmodulin-Dependent Protein Kinase II Activation in Intact Cardiomyocytes

Jeffrey R. Erickson, Ruchi Patel, Amanda Ferguson, Julie Bossuyt, Donald M. Bers

Rationale: Calcium/calmodulin-dependent protein kinase II (CaMKII) is a key mediator of intracellular signaling in the heart. However, the tools currently available for assessing dynamic changes in CaMKII localization and activation in living myocytes are limited.

Objective: We use Camui, a novel FRET-based biosensor in which full-length CaMKII is flanked by CFP and YFP, to measure CaMKII activation state in living rabbit myocytes.

Methods and Results: We show that Camui and mutant variants that lack the sites of CaMKII autophosphorylation (T286A) and oxidative regulation (CM280/1VV) serve as useful biosensors for CaMKIIδ activation state. Camui (wild-type or mutant) was expressed in isolated adult cardiac myocytes, and localization and CaMKII activation state were determined using confocal microscopy. Camui, like CaMKIIδ, is concentrated at the z-lines, with low baseline activation state. Camui activation increased directly with pacing frequency, but the maximal effect was blunted with the T286A, consistent with frequency-dependent phosphorylation of CaMKII at T286 mainly at high-frequency and high-amplitude Ca transients. Camui was also activated by 4 neurohormonal agonists. Angiotensin II and endothelin-1 activated Camui, largely through an oxidation-dependent mechanism, whereas isoproterenol- and phenylephrine-mediated mechanisms had a significant autophosphorylation-dependent component.

Conclusions: Camui is a novel, nondestructive tool that allows spatiotemporally resolved measurement of CaMKII activation state in physiologically functioning myocytes. This represents a first step in using Camui to elucidate key mechanistic details of CaMKII signaling in live hearts and myocytes. (Circ Res. 2011;109:729-738.)

Key Words: CaMKII ■ biosensor ■ FRET ■ Ca²⁺/calmodulin-dependent protein kinase II ■ oxidative stress ■ phosphorylation ■ signaling pathways

The multifunctional calcium/calmodulin (Ca²⁺/CaM)-dependent protein kinase II (CaMKII) translates numerous intracellular signals into downstream physiological effects. This plasticity of function derives from the unique structural features of CaMKII. Recent crystal structures show that the holoenzyme assembles as a dodecamer that comprises 2 stacked rings. Individual monomers feature 3 domains, a C-terminal association domain that directs dodecamer assembly, an N-terminal catalytic domain that interacts with substrates and performs kinase function, and a central regulatory domain that modulates the activity of CaMKII. In resting conditions, the regulatory domain forms a tight association with the catalytic domain, preventing substrate binding. When [Ca²⁺] is elevated, Ca²⁺/CaM binds to the regulatory domain of CaMKII and induces a conformational shift that disrupts association with the catalytic domain, resulting in a shift from an autoinhibited to an active state.¹ ²

In prolonged conditions of elevated Ca²⁺, intersubunit autophosphorylation occurs at the T286 residue (or T287, the numbering is isoform specific). Phosphorylation at T286 prevents the reassociation of the regulatory and catalytic domains, resulting in autonomous CaMKII activity that persists in the absence of Ca²⁺/CaM. The ability to shift from Ca²⁺-dependent to Ca²⁺-independent states allows CaMKII to transform shifts in the frequency or amplitude of Ca²⁺ transients into critical cellular outcomes, but how this signal integration occurs in cardiac myocytes is not understood.

An additional mechanism of autonomous CaMKII activation by reactive oxygen species (ROS) has been reported recently.⁵ After initial activation by Ca²⁺/CaM, M280/281
residues are subject to oxidation that blocks autoinhibition in a similar manner to T286 autophosphorylation. CaMKII is thus able to translate changes in redox potential from both acute and chronic stimuli into downstream physiological effects. But again, how this integrative signaling dovetails with other CaMKII activating signals in cardiac myocytes is poorly understood.

Hayashi (Takao et al) developed Camui, a fluorescence resonance energy transfer (FRET) biosensor based on the full-length sequence of CaMKII, to monitor the activation state of the kinase in neurons. Fluorescent proteins are added to the C- and N-terminal ends of the protein, allowing robust FRET in the compactly folded autoinhibited state. Activation of the kinase results in a conformational shift that is detected as a reduction in fluorescence transfer (Figure 1A). Expression of Camui in cells allows CaMKII activation state to be monitored both temporally and spatially.

Activation of CaMKII plays a key role in cardiac pathophysiology. CaMKII expression and activity are increased during heart failure, whereas genetic inhibition of cardiac CaMKII protects against the transition to structural heart disease. CaMKII also contributes to arrhythmogenesis through direct effects on ryanodine receptors sodium channels, and CaV1.2. ROS-dependent CaMKII activation is a critical mediator of angiotensin II (AngII)-induced myocyte apoptosis and plays an important role in structural remodeling after myocardial infarction. CaMKII is widely considered to be a potential therapeutic target in prevention of heart disease, yet the detailed signaling mechanisms and dynamic modulation of CaMKII function in intact cardiomyocytes are still largely unknown.

We developed Camui variants into adenoviral vectors to examine pathways of CaMKII activation by Ca\(^{2+}\) transients and neurohormonal agonists. Camui is a novel, nondestructive tool that allows the online measurement of CaMKII activity in physiologically functioning adult myocytes. We show that changes in FRET associated with a conformational shift of Camui are effective measures of CaMKII activation in living myocytes. In addition, we use Camui to demonstrate that CaMKII activity increases with enhanced pacing frequency (and elevated [Ca\(^{2+}\)], whereas a mutant Camui variant lacking the T286 site has a significantly blunted response to pacing frequency. Finally, stimulation of cardiac myocytes expressing wild-type (WT) or mutant variants of Camui reveal that AngII and endothelin-1 (ET-1) activate CaMKII by a primarily oxidation-dependent pathway, whereas isoproterenol (Iso) and phenylephrine (PE) activate CaMKII by a Ca\(^{2+}\) and autophosphorylation-dependent pathway. This study positions Camui as an important, emerging tool for examining CaMKII activation in cellular physiology and pathophysiology.

### Methods

#### Construction of Adenoviral Vectors Encoding Biosensors

The Camui construct was incorporated in adenoviruses with the use of the AdEasy adenoviral vector system (Qbiogene, Inc, Carlsbad, CA) to ensure high infection efficiency in the terminally differentiated adult ventricular myocytes. Mutant variants of Camui (T286A and MM280/281VV) were generated using the commercially available QuickChange site-directed mutagenesis kit (Stratagene) and likewise incorporated into adenovirus.

#### HEK293 Cell Transfection

HEK293 cells were cultured in Dulbecco modified Eagle medium (Invitrogen) with 5% fetal bovine serum and penicillin/streptomycin for 24 hours and then transiently transfected with expression plasmids encoding Camui using a mammalian transfection kit (Stratagene). Cells were cultured for an additional 36 hours after transfection. Camui expression was checked by fluorescence microscopy before experiments.
In Vitro Fluorescence and CaMKII Activity Assays

Fluorescence measurements were performed using an MS SpectraMax plate reader spectrophotometer (Molecular Devices). Excitation and emission slits were set at 4 nm. Excitation wavelength of 440 nm was used, and dual-photon counting emission detectors were set at 477 nm (F_{CFP}) and 527 nm (F_{YFP}), respectively. The cytosolic fraction of the transfected HEK cells was diluted in Ca^{2+}-free buffer containing 30 mmol/L Tris-HCl buffer (pH 7.5), 5 mmol/L MgCl_2, and protease inhibitors. Camui fluorescence was measured in the presence of 10 mmol/L CaM and 200 μmol/L Ca^{2+}. For some experiments, 1 mmol/L EGTA was used to chelate Ca^{2+}. Autophosphorylation conditions were measured in the presence of 1 mmol/L EGTA, 100 μmol/L ATP, and/or 1 μmol/L H_2O_2. Incubation time was 5 minutes to allow achievement of steady state. CaMKII kinase activity was confirmed by measuring incorporation of ATP into an artificial substrate, syntide-2, as previously described.8

Myocyte Isolation and Adenoviral Infection

All protocols involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the University of California, Davis Institutional Animal Care and Use Committee. Adult rabbit ventricular myocytes were isolated as previously described.10 Myocytes were seeded on laminin-coated coverslips in serum-free PC-1 medium (Lonza) supplemented with penicillin/streptomycin. Myocytes were infected for 2 hours with multiplicity of infection of 10 to 100 with adenovirus encoding Camui, followed by replacement with fresh medium. Infected cells were kept in culture for 36 hours, with a final replacement of fresh medium 1 hour before experiments.

Confocal Microscopy Imaging

Coverslips were mounted on the stage of an inverted microscope (Zeiss, LSM5 Pascal) equipped with a 40×1.4 NA water immersion objective lens. Argon laser excitation wavelengths were 458 nm for CFP and 514 nm for YFP. CFP emission fluorescence was measured by confocal microscopy at 485±15 nm, and YFP emitted fluorescence was measured at 535 nm. For some experiments, cells were field-stimulated at 0.25, 0.5, and 1 Hz. Some cells were treated with 1 μmol/L AngII, isoproterenol, PE, or ET-1. Confocal imaging was performed using an MS SpectraMax plate reader spectrophotometer (Molecular Devices). Excitation wavelength of 440 nm and emission slits were set at 4 nm. Excitation wavelength of 485 nm (FCFP) and 527 nm (FYFP), respectively. The cytosolic fraction of the transfected HEK cells was diluted in Ca^{2+}-free buffer containing 30 mmol/L Tris-HCl buffer (pH 7.5), 5 mmol/L MgCl_2, and protease inhibitors. Camui fluorescence was measured in the presence of 10 mmol/L CaM and 200 μmol/L Ca^{2+}. For some experiments, 1 mmol/L EGTA was used to chelate Ca^{2+}. Autophosphorylation conditions were measured in the presence of 1 mmol/L EGTA, 100 μmol/L ATP, and/or 1 μmol/L H_2O_2. Incubation time was 5 minutes to allow achievement of steady state. CaMKII kinase activity was confirmed by measuring incorporation of ATP into an artificial substrate, syntide-2, as previously described.8

Changes in Camui Fluorescence Report Changes in Kinase Conformation and Activity

Addition of Ca^{2+}/CaM to lysates from HEK cells expressing Camui resulted in a significant change in F_{CFP}/F_{YFP} compared with baseline, indicating a change in protein conformation (Figure 2A; first 2 sets of bars). This effect could be fully reversed by the addition of EGTA, as Ca^{2+} removal allows the kinase to return to an autoinhibited state (Figure 2A; third set of bars). However, treatment with Ca^{2+}/CaM in conditions favoring either autophosphorylation (+ATP) or oxidation (+H_2O_2) resulted in a sustained shift in F_{CFP}/F_{YFP} even after the addition of EGTA, thus demonstrating that CaMKII has undergone autonomous activation. These results match prior observations that autophosphorylation and oxidation preserve CaMKII activity by preventing reassociation of the regulatory and catalytic domains.3,5 Moreover, our results exclude the possibility that Camui functions only as a biosensor for CaM binding, because autophosphorylation/redox-dependent activation of CaMKII (and FRET change) is sustained after Ca^{2+} is sequestered and CaM dissociates from the kinase. Interestingly, treatment with both ATP and H_2O_2 in the presence of Ca^{2+}/CaM resulted in an additive effect on the shift in Camui fluorescence even after subsequent removal of Ca^{2+}/CaM, suggesting that the 2 autonomous mechanisms are distinct but potentially additive.

To further investigate the role of posttranslational modifications on CaMKII activity, we designed Camui variants lacking either the autophosphorylation site (T286A) or the redox-dependent activation of CaMKII (and FRET change) (CM280VV). As expected, the CM280VV mutant showed WT-like shift in fluorescence under autophosphorylation conditions (+ATP). However, the T286A mutant did not exhibit an autonomous shift in fluorescence under autophosphorylation conditions (+ATP). Conversely, the CM280VV mutant showed WT-like shift in fluorescence under autophosphorylation conditions, but not after H_2O_2 exposure. These observations further demonstrate the importance of the T286 and M280/281 sites in modulating CaMKII activity and further that autophosphorylation and oxidation are independent but complementary events.
We also performed traditional kinase assays to confirm that the shift in fluorescence observed for Camui is associated with a concomitant increase in kinase activity. Total kinase activity was measured as a function of incorporation of $^{32}$P into an artificial CaMKII substrate (syntide-2). We observed a significant increase in kinase activity for each Camui variant in the presence of Ca$^{2+}$/H11001/CaM (Figure 2B). Conditions favoring autophosphorylation preserved kinase activation levels for the WT and CM280/281VV Camui but not for the T286A mutant, whereas treatment with H$_2$O$_2$ resulted in autonomous activity for the WT and T286A but not the CM280/281VV Camui variant. These activity results corroborate our changes in FRET and demonstrate the efficacy of shifts in Camui fluorescence as a proxy for CaMKII activation state.

The Camui construct is based on full-length CaMKII, but the predominant isoform expressed in cardiac myocytes is CaMKII$\delta$. We performed additional activity assays using purified WT CaMKII$\delta$, as well as autophosphorylation and oxidation resistant mutants from a baculovirus system, to determine whether Camui activity mimics that of endogenous cardiac CaMKII$\delta$ (Online Figure I, A, available at http://circres.ahajournals.org). In every condition tested, CaMKII$\delta$ activity closely paralleled that observed with Camui in Figure 2B. We also plotted change in Camui FRET against the autonomous kinase activity observed for both the sensor and purified kinase (Online Figure I, B). This plot highlights 2 key results: (1) Camui FRET varies directly with autonomous kinase activity of both CaMKII$\delta$ and Camui, and (2) autonomous CaMKII activation by autophosphorylation and oxidation appear to be additive as measured by both change in FRET and kinase activity. Interestingly, direct activation of CaMKII by Ca$^{2+}$/CaM yields greater kinase activity than would be predicted by the observed change in Camui FRET. This is consistent with studies demonstrating that autonomous activation of CaMKII yields lower (but sustained) kinase activity compared with the direct CaM-induced mechanism.

To test whether the change in Camui fluorescence after H$_2$O$_2$ treatment was due to altered fluorophore fluorescence (as has been observed in a circularly permuted form of YFP), control cells were transfected with viruses encoding either CFP or YFP and treated as before. No significant redox-dependent change in FCFP or FYFP was observed (Figure 2C). This, along with the lack of effect of H$_2$O$_2$ on the CM280/281VV Camui mutant, indicates that the changes observed with H$_2$O$_2$ are due to ROS-dependent CaMKII activation involving CM280/281 and thus reflect the in vivo activation mechanism of the kinase.

We also tested the effects of 2 potent CaMKII inhibitors, KN93 and autocamtide-2 related inhibitory peptide (AIP), on
Camui FRET in activating conditions (+Ca\textsuperscript{2+}/CaM). The addition of 1 \(\mu\)mol/L KN-93 was sufficient to block FRET change associated with activation of Camui, whereas 1 \(\mu\)M AIP had no effect in similar conditions (Figure 2D, white bars). However, both inhibitors were confirmed to block Camui activity at these concentrations (Figure 2D, gray bars). We infer that KN-93 inhibits CaMKII activity by blocking the conformational shift associated with Ca\textsuperscript{2+}/CaM binding, whereas AIP permits the conformation change but inhibits CaMKII activity through a separate mechanism, possibly by binding to the catalytic domain (mimicking the regulatory domain) or hindering substrate binding. This observation suggests that Camui, a potential tool for screening CaMKII inhibitors, can distinguish between inhibitory mechanisms that rely on blocking CaMKII conformational shift versus those that rely on substrate exclusion.

Localization of Camui in Cardiomyocytes
Isolated rabbit cardiomyocytes were treated with a replication-deficient adenoviral construct encoding Camui. Images were taken 36 hours after exposure to the virus (Figure 3A). We observed a significant increase in total fluorescence at both the 477-nm and 527-nm emission wavelengths, indicating the expression of CFP and YFP, respectively. Line scan imaging shows periodic sarcomeric localization of Camui with highest expression at the z-lines, consistent with past observations of CaMKII localization using immunofluorescent imaging.\textsuperscript{5} Cells expressing Camui were loaded with di-8-ANEPPS, a fluorescent dye that strongly associates with t-tubules, to further examine Camui localization. After YFP bleaching, CFP and di-8-ANEPPS fluorescence were measured using line scan imaging (Online Figure II). Matching patterns of peak fluorescence for the 2 fluorophores further confirm the enrichment of Camui at the z-line. Ratiometric images were also generated by measuring \(\frac{FCFP}{FYFP}\) for cells expressing Camui, allowing us to determine whether Camui activation varies by subcellular localization (Figure 3B). We found that the basal Camui signal was slightly greater in the perinuclear space and cytoplasm than in the nucleus at rest.

To directly assess the FRET efficiency of Camui in cardiomyocytes, we performed selective high-intensity acceptor (YFP) photobleach and measured the resultant increase in donor (CFP) fluorescence. This confirms that true FRET is occurring, and \(FCFP\) (485 nm) increased by about 10% on 86% bleach of YFP (Figure 3C). This is consistent with a FRET efficiency of about 12%. Addition of ionomycin, which increases intracellular [Ca\textsuperscript{2+}] and activates Camui, virtually eliminated the increase in \(FCFP\) seen on YFP bleach. These results confirm that FRET occurs in Camui and is nearly abolished by activation of the sensor.

CaMKII tagged with GFP on the C-terminal association domain has been shown not to interfere with homomultimerization or heteromultimerization of CaMKII monomers.\textsuperscript{20} To test whether Camui participates in multimerization, we monitored the relationship between the rise in \(FCFP\) and
bleach of YFP (Figure 3D). A linear relationship would imply a 1:1 or monomeric Camui. In contrast, the curved relationship observed indicates that even when one YFP is bleached, the CFP on the same molecule can FRET with an alternate YFP; in other words, Camui can multimerize and produce intermolecular FRET. We interpret this finding as further evidence that the addition of CFP and YFP do not disrupt multimerization of Camui into a CaMKII-like holoenzyme.

Although the acceptor photobleach method is a sensitive, direct measurement of FRET efficiency, it is a terminal experimental protocol. To perform continuous, dynamic measurements in myocytes, we used continuous measurements of FCFP/FYFP.

Steady-State CaMKII Activity Is Increased in Paced Cells

The canonical mechanism of CaMKII activation is in response to Ca^{2+} transients. We used Camui to examine CaMKII activation resulting from excitation-contraction coupling. Rabbit cardiomyocytes were paced at different frequencies in Tyrode solution containing 1 or 2 mmol/L Ca^{2+} and expressing either WT or T286A Camui. WT Camui detected increased CaMKII activation as a direct function of pacing frequency (Figure 4, top panel). Additionally, steady-state CaMKII activation was enhanced at each stimulation frequency by increased [Ca^{2+}]_o. Notably, in resting cardiomyocytes, Camui appears to be very close to the deactivated level because inclusion of KN-93, and [Ca^{2+}]_o did not decrease the basal FCFP/FYFP signal appreciably (Figure 4, inset).

Interestingly, steady-state CaMKII activity levels measured by the WT and T286A mutant were indistinguishable at the slowest pacing frequencies (0.25 and 0.5 Hz), but activation of the T286A mutant was significantly reduced at a pacing frequency of 1 Hz compared with WT (Figure 4, bottom panel). Our results demonstrate that CaMKII activation state in cardiomyocytes is subject to acute regulation by the frequency and intensity of excitation-contraction coupling. Further, autophosphorylation at T286 contributes to CaMKII activation at higher frequency and [Ca^{2+}].

Neurohormonal Stimulation of Rabbit Myocytes Enhances CaMKII Activity

A number of additional intracellular signaling pathways are known to modulate CaMKII activity. These include neurohormonal stimulation, as has been observed with AngII and Iso. β-Adrenergic–dependent CaMKII activation also occurs through cAMP/Epac and cAMP/Ca^{2+}-independent pathways. To determine the effects of neurohormonal stimulation on CaMKII activation, we treated isolated rabbit cardiomyocytes expressing Camui with 4 different agonists known to play critical roles in cardiac signaling. Cells were exposed to agonist for 40 minutes (Figure 5A). Point measurements were used rather than continuous monitoring to limit fluorophore bleaching. All 4 agents caused a significant CaMKII activation (P<0.001 versus control) after 20 minutes, as measured by Camui. PE showed an intermediate time course of CaMKII activation, whereas Iso was slowest, with no significant change until 10 minutes after exposure. Interestingly, although Iso caused the slowest
initially response, the eventual peak intensity of CaMKII activation was the greatest. Note that all of these agonists activate CaMKII in quiescent myocytes at least as well as high-frequency Ca\(^{2+}\) transients.

The slow response of CaMKII to Iso stimulation was somewhat surprising. We hypothesized that the effects of Iso would be accelerated by Ca\(^{2+}\) transients. So we repeated the experiments using AngII and Iso, but this time in paced (0.5 Hz) rabbit cardiomyocytes expressing Camui. Pacing significantly altered the kinetics of CaMKII activation in response to Iso \((P<0.01\) for paced versus unpaced cells at 1 to 10 minutes), consistent with our hypothesis, but had more modest effects on the time course with AngII (Figure 5B). Additionally, the increased availability of Ca\(^{2+}\) in the paced cells resulted in higher peak CaMKII activity for both agonists.

To further elucidate the mechanism of Iso-induced Camui activation, we pretreated cells for 10 minutes with either 10 μmol/L thapsigargin, a potent and selective SERCA inhibitor, or 1 μmol/L okadaic acid, a phosphatase inhibitor. Pretreatment with thapsigargin blocked Camui activation for the 1- to 20-minute period after Iso treatment (Online Figure III, A). Conversely, okadaic acid accelerated the Iso-induced Camui activation \((P<0.05\) versus OA for 5- and 10-minute time points) and significantly increased peak steady-state Camui activation (Online Figure III, B).

**Mutant Camui Variants Elucidate Activation Mechanisms of CaMKII**

All 4 agonists used caused CaMKII activation. To further elucidate the mechanisms for activation associated with each, we repeated the stimulation experiments in cells expressing mutant variants of Camui lacking either the T286 phosphorylation or CM280/281 oxidation sites (Figure 6A). CaMKII activation by AngII and ET-1 was unchanged in the T286A mutant, but the CM280/281VV mutant showed a severely blunted response to both agonists. Peak CaMKII was reduced in the oxidation resistant mutant, and in the case of AngII, activity had returned to baseline levels within 20 minutes. These observations demonstrate that AngII and ET-1 modulate CaMKII activity by a pathway that importantly includes redox-dependent CaMKII activation for >50% of the maximal effect and up to 90% for AngII after 20 minutes (Figure 6B).

For Iso and PE, we observed no significant difference in CaMKII activation with the WT and CM280/281VV Camui variants. However, peak CaMKII activity in response to Iso and PE was reduced significantly in the phosphorylation-resistant mutant. Thus, in contrast to the oxidation-dependent mechanism of CaMKII activation by AngII and ET-1, we conclude that modulation of CaMKII activity by Iso and PE is driven significantly by T286 phosphorylation.

As an additional test of the role of oxidation in CaMKII activation by AngII and Iso, we pretreated cells expressing WT Camui with Trolox, a cell-permeable vitamin E derivative, to scavenge ROS. Peak CaMKII activation was unchanged in the presence of Trolox for cells treated with Iso (Figure 7). However, Trolox completely prevented the AngII-mediated CaMKII activation as measured by Camui. These observations recapitulate our previous findings that AngII stimulates CaMKII activation by a redox-dependent pathway.

**Discussion**

The regular Ca\(^{2+}\) transients that occur at each heartbeat and are modulated in amplitude and frequency during physiological conditions are expected to modify CaMKII activity in myocytes. Until now, the only methods to assess CaMKII activation state in myocytes have been destructive (eg, measures of target phosphorylation by phospho-antibodies), and direct activity measurements in cell lysates may not mimic cellular conditions. Measurements in cardiac myocytes with FRET-based Ca\(^{2+}\).CaM sensors and computational modeling have been steps toward enhanced understanding. The discovery that CaMKII can be activated by oxidation...
at the CM280/281 site, combined with the long-known connection between T286 phosphorylation and frequency-dependent CaMKII activation, further complicates our understanding of dynamic CaMKII activity regulation in the cellular environment. Probing for posttranslational modifications of Camui using traditional immunoblot methods can provide a snapshot of CaMKII activation state after the fact.

However, the development of biosensors such as Camui provides tools for monitoring the spatial and temporal status of CaMKII activation real-time in living myocytes. Indeed, our in vitro experiments demonstrate that the FRET change of Camui FCFP/FYFP is a good proxy for CaMKII activity. This method offers several advantages over traditional methods of determining CaMKII activity. Immunoblot of T286 phosphorylation has often been used as an indication of CaMKII activation, yet this method ignores canonical Ca2+/CaM activity and oxidation-dependent activity. Likewise, blotting for phosphorylation of a downstream CaMKII target, such as phospholamban, may account for only limited pools of CaMKII activity while missing others (eg, nuclear). Camui detects changes in CaMKII activation spatially within living myocytes. Camui will prove invaluable in future studies focused on the subcellular mechanisms that drive CaMKII signaling pathways in the heart.

Camui FCFP/FYFP is a good reporter of CaMKII activation by Ca2+/CaM, autophosphorylation, and oxidation, by sensing opening the regulatory-catalytic domain, but there are limitations. First, one cannot assume that the FCFP/FYFP signal is a linear readout of CaMKII activity. Although the autonomous activity through autophosphorylation or oxidation is a fairly linear function of Camui FCFP/FYFP over a wide range, direct Ca2+/CaM activation produces a higher activity for a given FCFP/FYFP signal (Online Figure I, B). This is consistent with prior work showing higher maximum CaMKII activity through Ca2+/CaM than with either autonomous pathway individually. It is worth noting that the 2 autonomous modes are roughly additive in both activity and FCFP/FYFP signal, and when combined, the CaMKII activity reaches roughly the same level as on maximal Ca2+/CaM activation.

Second, the increase in Camui FRET is not simple bimolecular FRET, because in the basal state CFP on the catalytic end of CaMKII can FRET with more than 1 YFP on the association domain (Figure 8B). This result is not surprising, based on prior work with GFP-tagged CaMKII and recent structural evidence for interplay between CaMKII subunits during activation. This could contribute to some signal FCFP/FYFP nonlinearity as catalytic domains become activated (Figure 8B), but, as we show, changes in FCFP/FYFP signal are a good proxy for CaMKII activity. Moreover, the fact that Camui is based on full-length CaMKII and that it multi-

merizes may provide the advantage that it behaves much like endogenous CaMKII, making the FCFP/FYFP structural signal of particular value (even if it is not a precise readout of enzymatic activity). Camui thus differs from FRETS

Figure 8. Models of the Camui sensor for both individual subunits and an assembled holoenzyme. A, FRET is expected to occur between the fluorophore pair of an inactive subunit. The conformational shift associated with CaMKII activation (eg, through CaM binding) should largely abolish fluorescence transfer. B, The geometry of the holoenzyme suggests the possibility that intersubunit FRET may occur between fluorophores from adjacent subunits.

merizes may provide the advantage that it behaves much like endogenous CaMKII, making the FCFP/FYFP structural signal of particular value (even if it is not a precise readout of enzymatic activity). Camui thus differs from FRET-based BsCaM sensors that we have used to monitor Ca2+/CaM binding to peptide CaM targets of different affinity as a readout of dynamic [Ca2+/CaM] signals in cardiac myocytes. These 2 types of sensors complement each other. Although BsCaM data provide information about Ca2+/CaM dynamics that could activate CaMKII and other CaM targets such as calcineurin, Camui reports on the actual impact of CaM as well as other factors (eg, autophosphorylation) on CaMKII structure and activity. In this regard, the dynamics of T286A Camui probably give a truer readout than BsCaM of the dynamics of CaM binding to real cellular CaMKII.

In addition, the specific roles of CaMKII phosphorylation and oxidation can be examined by using mutant forms of Camui lacking the target sites necessary for these modifications. This feature of Camui allows us to explore the mechanisms that translate upstream physiological signaling to downstream CaMKII activation. For example, our data demonstrate that AngII and ET-1 mediate CaMKII activity substantially through a redox-dependent pathway involving oxidation at amino acids 280 to 281 on CaMKII. These findings are in good agreement with a previously published study on activation of CaMKII by AngII. Interestingly, although other studies have established a link between ET-1 signaling and CaMKII activity, our data are the first to show that ET-1 regulates CaMKII in large part by oxidation and autonomous activation. In contrast to AngII and ET-1, we show that PE and Iso activate CaMKII through a pathway that is largely dependent on Ca2+ transient signaling and to a variable degree T286 phosphorylation, as demonstrated by reduced CaMKII activation of the T286A Camui mutant.
Remarkably, the kinetics for CaMKII activation by Iso in quiescent myocytes is very slow compared with the other agonists we tested. Part of the initial Iso-dependent activation of CaMKII also seems to depend on a functional SR (Online Figure III, A), and we speculate that this could be due to a PKA-dependent increase in SR Ca uptake (secondary to phospholamban phosphorylation) and enhancement of local Ca sparks.\textsuperscript{31} Conversely, the Iso-induced CaMKII activation was accelerated by both pacing the myocytes or inclusion of phosphatase inhibitors. Thus, for Iso exposure, CaMKII activation is a complex function of [Ca\textsuperscript{2+}]\textsubscript{i}, PKA, phosphatase, and probably additional pathways\textsuperscript{11,22,23} and autophosphorylation of CaMKII is an important contributor as well. It is also noteworthy that simple stimulation frequency at 2 mmol/L [Ca\textsuperscript{2+}]\textsubscript{i} does not achieve CaMKII activation levels seen with some GPCR agonists.

Because all known mechanisms of CaMKII activation require initial binding of Ca\textsuperscript{2+}/CaM to the autoinhibited kinase,\textsuperscript{4} CaMKII function is thought to be acutely sensitive to the intensity, duration, and frequency of Ca\textsuperscript{2+} transients. The extent to which this is the case is currently unknown, though much progress has been made using models of excitation-contraction coupling.\textsuperscript{26} The type of data that we have obtained may also fuel improvements in these mathematical models, enhancing their utility as well. We show that Camui is a powerful tool for detecting changes in CaMKII activity, with respect to frequency, Ca\textsuperscript{2+} transient amplitude, and interaction with GPCR signaling. A clear direction of future study is examining the kinetics of Camui signaling on a beat-to-beat basis, as well as further efforts to ascertain the extent of CaMKII activation in response to acute Ca\textsuperscript{2+} signaling and how it may synergize in detail with these GPCR-linked activation pathways. Such data would lend valuable insight for detailed tuning of models and our integrated understanding of CaMKII signaling in heart.

Increased CaMKII activity is a common feature of structural heart disease and sudden heart failure in patients and in animal models, whereas inhibition\textsuperscript{22,33} and knockout\textsuperscript{34,35} of CaMKII reduces apoptosis and improves mortality\textsuperscript{36} in structural heart disease models. These findings have garnered attention for CaMKII as a potential therapeutic target for treating heart failure and arrhythmias.\textsuperscript{37} Camui represents a powerful tool to aid in the development of treatment strategies centered on CaMKII. Using Camui in combination with models of structural heart disease would provide novel mechanistic insight into CaMKII regulation in the context of the failing heart. Additionally, the ability to monitor kinase activity in cells expressing Camui would benefit future efforts to design therapeutics targeted at cardiac CaMKII.

Acknowledgments
We thank Dr Yasuonri Hayashi (RIKEN Brain Science Institute), for his generous gift of the Camui construct.

Sources of Funding
This study was supported by National Institutes of Health (NIH) grants T32 HL86350 (J.R.E.); NIH grant R01 HL103933 and an American Heart Association Scientist Development Grant 053512N (J.B.); and NIH grants P01 HL080101 and R37 HL30077 and the Fondation Ledoux Transatlantic CaMKII Alliance (D.M.B.).

Disclosures
None.

References
Camui represents a critical tool in the translation of CaMKII research into clinical applications. Camui has emerged as a critical mediator of cardiac physiology, particularly during the transition from healthy to failing myocardium. Thus, CaMKII is a potential target for future therapeutic approaches in the prevention of heart disease. However, the detailed mechanisms of CaMKII activation in cells are not fully understood. Here, we introduce a method for monitoring CaMKII activation state using the fluorescent biosensor Camui. This sensor can be used to measure CaMKII activity in intact cells, which is greatly advantageous compared with existing destructive methods because it allows changes in CaMKII activity to be observed over time and within subcellular locations. We show that CaMKII activity is influenced by both pacing rate and neurohormonal stimulation. Additionally, we use mutant forms of Camui lacking key regulatory sites to show that CaMKII activation state is determined by distinct molecular mechanisms that are specific to the activating stimulus. Camui will not only be an advantageous tool for monitoring CaMKII activation state in intact cardiac myocytes using the fluorescent biosensor Camui, but it allows changes in CaMKII activity to be observed over time and within subcellular locations. We show that CaMKII activity is influenced by both pacing rate and neurohormonal stimulation. Additionally, we use mutant forms of Camui lacking key regulatory sites to show that CaMKII activation state is determined by distinct molecular mechanisms that are specific to the activating stimulus. Camui will not only be an invaluable tool for future research on the mechanisms of CaMKII activation in the heart but it will also provide new insight into clinical approaches aimed at the prevention of arrhythmia and sudden heart failure.

**Novelty and Significance**

**What Is Known?**

- Calcium/calmodulin-dependent kinase II (CaMKII) translates a broad range of upstream signaling mechanisms to downstream physiological effects in the heart.
- Activation of CaMKII is a critical step in the transition to arrhythmia and heart failure.
- CaMKII activity is regulated by several mechanisms, including calcium transient frequency and redox potential.

**What New Information Does This Article Contribute?**

- We present a novel method for dynamic real-time monitoring of CaMKII activity in intact cardiac myocytes using the fluorescent biosensor Camui.
- Camui allows spatial and temporal resolution of CaMKII activation state in living cells.
- Signaling mechanisms known to enhance CaMKII activity do so through distinct molecular mechanisms.
- Camui represents a critical tool in the translation of CaMKII research into clinical applications.
Fluorescence Resonance Energy Transfer–Based Sensor Camui Provides New Insight Into Mechanisms of Calcium/Calmodulin-Dependent Protein Kinase II Activation in Intact Cardiomyocytes

Jeffrey R. Erickson, Ruchi Patel, Amanda Ferguson, Julie Bossuyt and Donald M. Bers

Circ Res. 2011;109:729-738; originally published online August 11, 2011;
doi: 10.1161/CIRCRESAHA.111.247148

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/109/7/729

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2011/08/11/CIRCRESAHA.111.247148.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL
for
The novel FRET-based sensor Camui provides new insight into mechanisms of CaMKII activation in intact cardiomyocytes
Jeffrey R. Erickson, Ruchi Patel, Amanda Ferguson, Julie Bossuyt, and Donald M. Bers

METHODS

Construction of Adenoviral Vectors Encoding Biosensors
The Camui construct was incorporated in adenoviruses using the AdEasy™ adenoviral vector system (Qbiogene, Inc., Carlsbad, CA) to ensure high infection efficiency in the terminally differentiated adult ventricular myocytes. Mutant variants of Camui (T286A and MM280/281VV) were generated using the commercially available QuickChange site directed mutagenesis kit (Stratagene), and likewise incorporated into adenovirus.

HEK293 Cell Transfection
HEK293 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 5% fetal bovine serum and penicillin/streptomycin for 24 h and then transiently transfected with expression plasmids encoding Camui using a mammalian transfection kit (Stratagene). Cells were cultured for an additional 36 hours post transfection. Camui expression was checked by fluorescence microscopy prior to experiments.

In Vitro Fluorescence and CaMKII activity assays
Fluorescence measurements were performed using a MS SpectraMax plate reader spectrophotometer (Molecular Devices). Excitation and emission slits were set at 4 nm. Excitation wavelength of 440 nm was used, and dual photon counting emission detectors were set at 477 nm (FCFP) and 527 nm (FYFP), respectively. The cytosolic fraction of the transfected HEK cells was diluted in Ca²⁺-free buffer containing 50 mM Tris-HCl buffer (pH 7.5), 5 mM MgCl₂, and protease inhibitors. Camui fluorescence was measured in the presence of 10 μM CaM and 200 μM Ca²⁺. 

For some experiments, 1 mM EGTA was used to chelate Ca²⁺. Autonomous CaMKII activity was measured in the presence of 1 mM EGTA, 100 μM ATP and/or 1 μM H₂O₂. Incubation time was five minutes to allow achievement of steady state. Measurements were made in black/clear bottom tissue culture plates (Costar) at 37°C. CaMKII kinase activity was confirmed by measuring incorporation of ³²P-ATP into an artificial substrate, syntide-2, as previously described. Assays were performed on either purified kinase or on HEK cell lysates expressing Camui, as described in the Results section. Incubation times were five minutes as before, to achieve steady state. Data were normalized against background measurements lacking syntide-2.

Myocyte Isolation and Adenoviral Infection
All protocols involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the University of California, Davis Institutional Animal Care and Use Committee. Adult rabbit ventricular myocytes were isolated as previously described. Myocytes were seeded on laminin-coated coverslips in serum-free PC-1 medium (Lonza) supplemented with penicillin/streptomycin. Myocytes were infected for 2 hours at multiplicity of infection of 10–100 with adenovirus encoding Camui, followed by replacement with fresh medium. Infected cells were kept in culture for 36 hours with one final replacement of fresh medium 1 hr before experiments.

Confocal Microscopy Imaging
Cover slips were mounted on the stage of an inverted microscope (Zeiss, LSM5 Pascal) equipped with a 40× 1.4 NA water immersion objective lens. Argon laser excitation wavelengths were 458 nm for CFP and 514 nm for YFP. CFP emission fluorescence was measured by confocal microscopy at 485 ± 15 nm, while YFP emitted fluorescence was measured at 535 nm. For some experiments, cells were field stimulated at 0.25, 0.5, and 1 Hz. Some cells were treated with 1 μM angiotensin II, isoproterenol, phenylephrine, or endothelin-1. All myocyte experiments were performed in Tyrode solution containing 1 mM Ca²⁺ unless otherwise noted. For each experimental condition, a minimum of 30 cells (3 rabbits, 10 cells from each) was analyzed. Image-J software was used for image analysis.

Statistics
Pooled data are represented as the means ± S.E. Statistical comparisons were made using repeated two-way analysis of variance and paired Student’s t test where applicable. p < 0.05 was considered significant.

REFERENCES
Supplemental Figure I – Change in Camui FRET correlates with autonomous CaMKII activation. (A) Activity assays show significant activation of CaMKIIδ (predominant cardiac form) in all conditions that induced Camui activation. (B) Change in donor to acceptor fluorescence ratio scales linearly with autonomous activity (above background, different treatments indicated by colors) for both the Camui sensor (filled) and CaMKIIδ (open symbols). Direct Ca/CaM activation (black symbols) have higher activity than regression line for given $F_{CFP}/F_{YFP}$. 

Supplemental Figure I
Supplemental Figure II – Camui targeting at the myofilament z-lines was confirmed using di-8-ANEPPS staining of rabbit myocytes. To avoid spectral overlap of Camui and di-8-ANEPPS, high intensity 514nm laser light was used to photobleach YFP. Imaging parameters for Camui and di-8-ANEPPS were respectively 440 and 488 nm for excitation and BP 465-495 and 650-750 for emission. Shown is a sample plot profile of Camui and di-8-ANEPPS fluorescence intensities in the cytosol.
Supplemental Figure III

Supplemental Figure III – Isoproterenol mediated Camui activation in the presence of thapsigargin (TG) and okadaic acid (OA). (A) 10 min pretreatment with 10 µM TG blocks Iso induced Camui activation. (B) 10 min Pretreatment with 1 µM OA partially ablates the slow response of Camui toIso and increases peak change in FRET. * indicates p<0.05 vs. control.